COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,620 Articles (22,913 medRxiv, 8,707 bioRxiv)

Most recent first Previous |  Page 3114: Articles 31131-31140  | Next

Discovery of a 382-nt deletion during the early evolution of SARS-CoV-2
Su, Y., Anderson, D., Young, B., Zhu, F., Linster, M., Kalimuddin, S., Low, J., Yan, Z., Jayakumar, J., Sun, L., Yan, G., Mendenhall, I., Leo, Y.-S., Lye, D., Wang, L.-F., Smith, G.
10.1101/2020.03.11.987222 — Posted: 2020-03-12 Discussion: Onsite
Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2
Xiong, R., Zhang, L., Li, S., Sun, Y., Ding, M., Wang, Y., Zhao, Y., Wu, Y., Shang, W., Jiang, X., Shan, J., Shen, Z., Tong, Y., Xu, L., Chen, Y., Liu, Y., Zou, G., Lavillete, D., Zhao, Z., Wang, R., Zhu, L., Xiao, G., Lan, K., Li, H., Xu, K.
10.1101/2020.03.11.983056 — Posted: 2020-03-12 Discussion: Onsite
Rigidity, normal modes and flexible motion of a SARS-CoV-2 (COVID-19) protease structure.
Wells, S. A.
10.1101/2020.03.10.986190 — Posted: 2020-03-12 Discussion: Onsite
A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
Ge, Y., Tian, T., Huang, S., Wan, F., Li, J., Li, S., Yang, H., Hong, L., Wu, N., Yuan, E., Cheng, L., Lei, Y., Shu, H., Feng, X., Jiang, Z., Chi, Y., Guo, X., Cui, L., Xiao, L., Li, Z., Yang, C., Miao, Z., Tang, H., Chen, L., Zeng, H., Zhao, D., Zhu, F., Shen, X., Zeng, J.
10.1101/2020.03.11.986836 — Posted: 2020-03-12
The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15
Matsuyama, S., Kawase, M., Nao, N., Shirato, K., Ujike, M., Kamitani, W., Shimojima, M., Fukushi, S.
10.1101/2020.03.11.987016 — Posted: 2020-03-12 Discussion: Onsite
A human monoclonal 1 antibody blocking SARS-CoV-2 infection
Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A. D. M. E., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F., Bosch, B.-J.
10.1101/2020.03.11.987958 — Posted: 2020-03-12 Discussion: Onsite
The SARS-CoV-2 exerts a distinctive strategy for interacting with the ACE2 human receptor
Brielle, E. S., Schneidman, D., Linial, M.
10.1101/2020.03.10.986398 — Posted: 2020-03-12
Development of Reverse Transcription Loop-mediated Isothermal Amplification (RT-LAMP) Assays Targeting SARS-CoV-2
Park, G.-S., Ku, K., Beak, S.-H., Kim, S. J., Kim, S. I., Kim, B.-T., Maeng, J.-S.
10.1101/2020.03.09.983064 — Posted: 2020-03-12
Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
Xia, S., Liu, M., Wang, C., Xu, W., Lan, Q., Feng, S., Qi, F., Bao, L., Du, L., Liu, S., Qin, C., Sun, F., Shi, Z., Zhu, Y., Jiang, S., Lu, L.
10.1101/2020.03.09.983247 — Posted: 2020-03-12 Discussion: Onsite
Clinical Characteristics of Two Human to Human Transmitted Coronaviruses: Corona Virus Disease 2019 versus Middle East Respiratory Syndrome Coronavirus.
Xu, P., Sun, G.-D., Li, Z.-Z.
10.1101/2020.03.08.20032821 — Posted: 2020-03-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).